Paushak makes phosgene-based specialty chemical intermediates used by pharma and agrochemical manufacturers.
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 12 |
| Reserves | 224 | 269 | 302 | 351 | 405 | 462 | 477 | 479 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 25 | 60 | 77 |
| Other Liabilities | 43 | 57 | 61 | 61 | 73 | 81 | 80 | 92 |
| Total Liabilities | 270 | 329 | 367 | 415 | 481 | 572 | 620 | 660 |
| AssetsFixed Assets | 41 | 51 | 147 | 149 | 152 | 141 | 183 | 377 |
| CWIP | 16 | 68 | 8 | 7 | 29 | 190 | 205 | 26 |
| Investments | 163 | 154 | 151 | 182 | 223 | 139 | 131 | 150 |
| Other Assets | 50 | 56 | 61 | 78 | 77 | 102 | 100 | 107 |
| Total Assets | 270 | 329 | 367 | 415 | 481 | 572 | 620 | 660 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 24 | 41 | 30 | 44 | 43 | 56 | 38 | 54 |
| Cash from Investing | 0 | -39 | -29 | -42 | -38 | -50 | -57 | -95 |
| Cash from Financing | -23 | -2 | -2 | -2 | -4 | -5 | 19 | 42 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 13 | 27 | -26 | -4 | 28 | 17 | -122 | -34 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (230.7×) and current (28.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -9.6% growth and a 29× exit, ₹460 only delivers your return if you pay ₹109. The price is currently baking in 17% growth.
EPS grows -9.6%/yr for 5 years, then fades to 6% over 2, exits at 29×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -9.6% | 14.43 |
| FY28 | -9.6% | 13.04 |
| FY29 | -9.6% | 11.79 |
| FY30 | -9.6% | 10.66 |
| FY31 | -9.6% | 9.64 |
| FY32 | -1.8% ·fade | 9.46 |
| FY33 | 6.0% ·fade | 10.03 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.